GeneEx

GeneEx, Inc. was a clinical-stage biopharmaceutical company primarily focused on developing therapeutic products for the treatment of cancer and other life-threatening diseases through the regulation of gene expression. The company's core technology centered on a proprietary platform designed to control the expression of specific genes involved in disease progression, such as those related to hypoxia and angiogenesis. Its lead research programs targeted the inhibition of Hypoxia-inducible factor 1-alpha (HIF-1α) and Vascular endothelial growth factor (VEGF) to treat solid tumors and various ocular conditions. GeneEx was eventually integrated into larger biotechnology frameworks following its acquisition, contributing its intellectual property in gene regulation to broader oncology and ophthalmology pipelines.